专利号:US-2025101045-A1 优先权日:2022-01-18 标题:Synthesis of boron-containing amidoxime reagents and their application to synthesize functionalized oxadiazole and quinazolinone derivatives 发明人:DAS BHASKAR 权利人:LONG ISLAND UNIV 摘要:The present disclosure is concerned with borylated amidoximes useful in the synthesis of biologically relevant drug-like molecules, including functionalized oxadizole and quinazolinone derivatives. Also disclosed are methods of making borylated amidoximes, methods of making functionalized oxadiazole and quinazolinone compounds using the amidoximes, and functionalized oxadiazole and quinazolinone compounds prepared from borylated amidoximes. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
专利号:US-2023212216-A1 优先权日:2019-12-20 标 题:Synthesis of lactone derivatives and their use in the modification of proteins 发明人:MORRIS ALEXANDER REDFERN; SUTOV GRIGORIJ; BRUNE KARL DIETRICH 权利人:GENIE BIOTECH UK LTD 摘要:Site-specific modifications of proteins are desirable in biotechnological applications such as biopharmaceuticals, immunotherapy, vaccines, and are useful in chemical biology. Gluconoylation is a non-enzymatic, covalent, post-translational modification commonly observed on N-terminal His-Tags bearing proteins. We synthesized glucono-1,5-lactone derivatives, including azido variants for selective acylation. High yield acylation is achieved by simply mixing derivatives with target protein amidst diverse conditions of temperatures, aqueous buffers, excipients, or complex cell lysate.
专利号:US-10906888-B2 优先权日:2016-07-14 标 题:Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme 发明人:CASIMIRO-GARCIA AGUSTIN; STROHBACH JOSEPH WALTER; HEPWORTH DAVID; LOVERING FRANK ELDRIDGE; CHOI CHULHO; ALLAIS CHRISTOPHE PHILIPPE; WRIGHT STEPHEN WAYNE 权利人:PFIZER 摘要:Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
专利号:WO-2023141114-A2 优先权日:2022-01-18 标 题:Synthesis of boron-containing amidoxime reagents and their application to synthesize functionalized oxadiazole and quinazolinone derivatives
专利号:US-10308615-B2 优先权日:2015-05-29 标 题:Heterocyclic compounds as inhibitors of Vanin-1 enzyme 发明人:CASIMIRO-GARCIA AGUSTIN; CONDON JEFFREY SCOTT; FLICK ANDREW CHRISTOPHER; GOPALSAMY ARIAMALA; KIRINCICH STEVEN J; MATHIAS JOHN PAUL; STROBACH JOSEPH WALTER; XIANG JASON SHAOYUN; XING LI HUANG; WANG XIAOLUN 权利人:PFIZER 摘要:Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
专利号:AU-2020409711-A1 优先权日:2019-12-20 标题 :Synthesis of lactone derivatives and their use in the modification of proteins
1: Thombre A, Tse S, Yeoh T, Chen R, North R, Brown M. Ex vivo (human skin) and in vivo (minipig) permeation of propylene glycol applied as topical crisaborole ointment, 2. Int J Pharm. 2019 Nov 21:118847. doi: 10.1016/j.ijpharm.2019.118847. [Epub ahead of print] doi: 10.1016/j.jaci.2019.06.047. Epub 2019 Aug 13. doi: 10.1002/bmc.4664. Epub 2019 Aug 29. doi: 10.1007/s40257-019-00450-w. 7: Pharmacoeconomic Review Report: Crisaborole Ointment, 2% (Eucrisa): (Pfizer Canada Inc.): Indication: For topical treatment of mild-to-moderate atopic dermatitis in patients two years of age and older [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Apr. Available from http://www.ncbi.nlm.nih.gov/books/NBK542516/ Available from http://www.ncbi.nlm.nih.gov/books/NBK542348/ No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK542403/ doi: 10.1097/DER.0000000000000488. doi: 10.1111/jdv.15712. Epub 2019 Jul 7. doi: 10.1080/14656566.2019.1604688. Epub 2019 Apr 19. Review. doi: 10.2340/00015555-3181. doi: 10.1111/pde.13793. Epub 2019 Mar 5. doi: 10.1016/j.jaad.2018.10.054. Epub 2018 Nov 2. doi: 10.1007/s13555-018-0263-0. Epub 2018 Oct 22.
合成参考文献
摘要:Murrell DF, Gebauer K, Spelman L, Zane LT. Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study. J Drugs Dermatol. 2015 Oct;14(10):1108–12. 参考文献:10.1007/s13555-016-0167-9 摘要:Griffiths CE, van de Kerkhof P, Czarnecka-Operacz M. Psoriasis and Atopic Dermatitis. Dermatol Ther (Heidelb). 2017 Jan;7(Suppl 1):31–41. 参考文献:10.1080/13696998.2018.1470520 摘要:Clark R, Bozkaya D, Levenberg M, Faulkner S, Smith TW, Gerber RA. Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2%. Journal of Medical Economics. 2018 May 21;21(8):770–7. doi: 10.1080/13696998.2018.1470520. 参考文献:10.1007/s40257-019-00450-w 摘要:Callender VD, Alexis AF, Stein Gold LF, Lebwohl MG, Paller AS, Desai SR, Tan H, Ports WC, Zielinski MA, Tallman AM. Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups. American Journal of Clinical Dermatology. 2019 Jul 01;20(5):711–23. doi: 10.1007/s40257-019-00450-w.